How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree on the proposal for withdrawing this technology appraisal? If not, please can you state why you disagree.

  • Question on Consultation

    Are you aware of any implications for UK clinical practice on withdrawing this technology appraisal? If so, please describe.

2025 surveillance of electroconvulsive therapy (technology appraisal guidanceTA59, NICE guideline NG222, NICE guideline CG178, NICE guideline CG185, NICE guideline CG192)

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Overall proposal

We propose that TA59 is withdrawn and recommendations for the use of ECT are moved to the relevant condition guidelines as was done for the recommendations on ECT use in depression (NG222).

  • New evidence indicates that the recommendations in TA59 on the use of ECT in schizophrenia could be updated in guideline CG178.

  • New evidence supports the existing recommendations in TA59 for bipolar disease. The recommendations will be incorporated in guideline CG185.

  • New evidence supports the existing recommendations in TA59 for catatonia. The recommendations will be withdrawn. We are aware of ongoing work at Royal College of Physiatrists and will work with the College to ensure that advice on the use of ECT for catatonia is provided to the system.

We propose not to update recommendations on the use of ECT in Antenatal and postnatal mental health: Clinical management and service guidance (CG192), as new evidence supports the existing recommendations.